Abstract | BACKGROUND: METHODS: RESULTS: Twenty-seven SARS-CoV-2 pneumonia patients received one 400 mg dose of tocilizumab. Interleukin (IL)-6 was the predominant cytokine detected at tocilizumab treatment. Significant reductions in temperature and CRP were seen post- tocilizumab. However, 4 patients did not show rapid CRP declines, of whom 3 had poorer outcomes. Oxygen and vasopressor requirements diminished over the first week post- tocilizumab. Twenty-two patients required mechanical ventilation; at last follow-up, 16 were extubated. Adverse events and serious adverse events were minimal, but 2 deaths (7.4%) occurred that were felt unrelated to tocilizumab. CONCLUSIONS: Compared to published reports on the morbidity and mortality associated with SARS-CoV-2, tocilizumab appears to offer benefits in reducing inflammation, oxygen requirements, vasopressor support, and mortality. The rationale for tocilizumab treatment is supported by detection of IL-6 in pathogenic levels in all patients. Additional doses of tocilizumab may be needed for those showing slow declines in CRP. Proof of efficacy awaits randomized, placebo-controlled clinical trials.
|
Authors | Stanley C Jordan, Phillip Zakowski, Hai P Tran, Ethan A Smith, Cyril Gaultier, Gregory Marks, Rachel Zabner, Hayden Lowenstein, Jillian Oft, Benjamin Bluen, Catherine Le, Rita Shane, Noriko Ammerman, Ashley Vo, Peter Chen, Sanjeev Kumar, Mieko Toyoda, Shili Ge, Edmund Huang |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 71
Issue 12
Pg. 3168-3173
(12 15 2020)
ISSN: 1537-6591 [Electronic] United States |
PMID | 32575124
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected]. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- tocilizumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
- COVID-19
- Compassionate Use Trials
- Humans
- Male
- Middle Aged
- SARS-CoV-2
- Treatment Outcome
|